1. Home
  2. ARBE vs ONCY Comparison

ARBE vs ONCY Comparison

Compare ARBE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbe Robotics Ltd.

ARBE

Arbe Robotics Ltd.

N/A

Current Price

$0.55

Market Cap

79.1M

Sector

Technology

ML Signal

N/A

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

N/A

Current Price

$0.56

Market Cap

80.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARBE
ONCY
Founded
2015
1998
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.1M
80.5M
IPO Year
2021
2002

Fundamental Metrics

Financial Performance
Metric
ARBE
ONCY
Price
$0.55
$0.56
Analyst Decision
Buy
Buy
Analyst Count
3
6
Target Price
$2.75
★ $4.14
AVG Volume (30 Days)
★ 1.2M
1.0M
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$301.71
N/A
Revenue Next Year
$427.31
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.54
52 Week High
$2.73
$1.32

Technical Indicators

Market Signals
Indicator
ARBE
ONCY
Relative Strength Index (RSI) 31.83 22.95
Support Level N/A N/A
Resistance Level $0.91 $0.89
Average True Range (ATR) 0.04 0.04
MACD -0.01 -0.01
Stochastic Oscillator 16.93 12.50

Price Performance

Historical Comparison
ARBE
ONCY

About ARBE Arbe Robotics Ltd.

Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Share on Social Networks: